Intra-Cellular Therapies, Inc. (ITCI)

Intra-Cellular Therapies Stock Forecast

Stock Price Forecast

The 12 analysts with 12-month price forecasts for Intra-Cellular Therapies stock have an average target of 106.58, with a low estimate of 74 and a high estimate of 132. The average target predicts a decrease of -19.16% from the current stock price of 131.85.

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$74	$106.58	$103	$132
Change	-43.87%	-19.16%	-21.88%	+0.12%

* Price targets were last updated on Feb 24, 2025.

Analyst Ratings

The average analyst rating for Intra-Cellular Therapies stock from 13 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	5	5	5	3	2	2
Buy	5	5	5	4	4	4
Hold	2	2	2	6	7	7
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	12	12	12	13	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Graig Suvannavejh Mizuho	Mizuho	Buy → Hold Downgrades $140 → $132	Buy → Hold	Downgrades	$140 → $132	+0.12%	Feb 24, 2025
Ami Fadia Needham	Needham	Hold Reiterates n/a	Hold	Reiterates	n/a	n/a	Feb 21, 2025
Sumant Kulkarni Canaccord Genuity	Canaccord Genuity	Strong Buy → Hold Downgrades $119 → $132	Strong Buy → Hold	Downgrades	$119 → $132	+0.12%	Jan 31, 2025
Brian Abrahams RBC Capital	RBC Capital	Buy → Hold Downgrades $108 → $132	Buy → Hold	Downgrades	$108 → $132	+0.12%	Jan 22, 2025
David Amsellem Piper Sandler	Piper Sandler	Buy → Hold Downgrades $107 → $132	Buy → Hold	Downgrades	$107 → $132	+0.12%	Jan 14, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

966.26M

Increased by 41.92%

from 680.85M

Revenue Next Year

1.57B

Increased by 62.07%

from 966.26M

EPS This Year

0.20

from -0.72

EPS Next Year

4.03

Increased by 1,917.44%

from 0.20

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	22.81M	83.80M	250.31M	464.37M	680.85M	966.26M	1.57B	2.22B
Revenue Growth	37,537.14%	267.35%	198.69%	85.52%	46.62%	41.92%	62.07%	41.44%
EPS	-3.23	-3.50	-2.72	-1.46	-0.72	0.20	4.03	8.72
EPS Growth	-	-	-	-	-	-	1,917.44%	116.50%
Forward PE	-	-	-	-	-	660.47	32.74	15.12
No. Analysts	-	-	-	-	-	14	14	10

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029
High	1.1B	1.8B	2.5B
Avg	966.3M	1.6B	2.2B
Low	877.5M	1.5B	1.9B

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029
High	57.4%	81.2%	58.8%
Avg	41.9%	62.1%	41.4%
Low	28.9%	50.2%	21.6%

EPS Forecast

EPS	2025	2026	2027	2028	2029
High	1.33	5.63	11.60
Avg	0.20	4.03	8.72
Low	-0.50	1.95	5.15

EPS Growth

EPS Growth	2025	2026	2027	2028	2029
High	-	2,719.3%	188.1%
Avg	-	1,917.4%	116.5%
Low	-	876.9%	28.0%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.